Becton, Dickinson Announces Appointment of New Board Members

Details

Huffines and Jacqueline Wright as new members of its Board of Directors, effective December 1, 2025. Both Huffines and Wright will receive restricted stock units valued at $33,575 as part of their compensation, which is prorated from the effective date through BD's 2026 Annual Meeting of Shareholders.

Items reported

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.